Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker MGNX · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Oct 30, 2026 | A Study of MGC030 in Participants With Advanced Solid Tumors NCT07822399 · Urothelial Cancer, GastroEsophageal Cancer MGC030 | MGNX MacroGenics | Phase 1 | Recruiting was not yet recruiting | 314 | Sep 2028 | Registry ↗ |
| Oct 28, 2026 | A Study of MGC026 in Participants With Advanced Solid Tumors NCT06242470 · Advanced Solid Tumor, Advanced Cancer MGC026 Dose Escalation, MGC026 Dose for Expansion | MGNX MacroGenics | Phase 1 | Recruiting | 394 | Oct 2028 | Registry ↗ |
| Jul 28, 2026 | A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies NCT05362773 · Leukemia, Acute Myeloid, Myelodysplastic Syndromes MGD024 | MGNX MacroGenics | Phase 1 | Active, not recruiting | 130 | Nov 2026 | Registry ↗ |
| Jun 2, 2026 | A Study of Lorigerlimab in Participants With Advanced Solid Tumors NCT06730347 · Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallo… Lorigerlimab | MGNX MacroGenics | Phase 2 | Recruiting | 80 | Jul 2027 | Registry ↗ |
| May 22, 2026 | A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castratio… NCT05848011 · Androgen-Independent Prostatic Cancer, Androgen-Independent… lorigerlimab, docetaxel | MGNX MacroGenics | Phase 2 | Completed | 154 | Feb 19, 2026 | Registry ↗ |
| Apr 27, 2026 | A Study of MGC028 in Participants With Advanced Solid Tumors NCT06723236 · Advanced Solid Tumors, NSCLC Adenocarcinoma MGC028 | MGNX MacroGenics | Phase 1 | Recruiting | 124 | Nov 2026 | Registry ↗ |
| Feb 9, 2026 | A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate… NCT05551117 · Castration-Resistant Prostatic Cancer, Androgen-Independent… vobramitamab duocarmazine 2.0 mg (Arm A), vobramitamab duoc… | MGNX MacroGenics | Phase 2 | Terminated | 192 | Jul 4, 2024 | Registry ↗ |
| Oct 14, 2025 | A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors NCT05293496 · Advanced Solid Tumor, Castration-Resistant Prostatic Cancer vobramitamab duocarmazine, lorigerlimab | MGNX MacroGenics | Phase 1 | Completed | 31 | Jun 24, 2025 | Registry ↗ |
| Aug 11, 2025 | Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Ca… NCT02475213 · Melanoma, Head and Neck Cancer Enoblituzumab Schedule 1, Pembrolizumab | MGNX MacroGenics | Phase 1 | Completed | 146 | Aug 18, 2021 | Registry ↗ |
| Jul 31, 2025 | MGC018 With or Without MGA012 in Advanced Solid Tumors NCT03729596 · Squamous Cell Carcinoma of Head and Neck, Triple Negative B… vobramitamab duocarmazine | MGNX MacroGenics | Phase 1/2 | Terminated | 143 | Mar 18, 2023 | Registry ↗ |
| Jun 8, 2025 | Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gast… NCT04082364 · Gastric Cancer, Gastroesophageal Junction Cancer margetuximab, Retifanlimab | MGNX MacroGenics | Phase 2/3 | Completed | 82 | Jan 15, 2024 | Registry ↗ |
| Mar 28, 2025 | A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy NCT05261191 · Human Immunodeficiency Virus I Infection, Immunodeficiency… MGD020, MGD014 | MGNX MacroGenics | Phase 1 | Completed | 17 | May 29, 2024 | Registry ↗ |
| Mar 17, 2025 | Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesopha… NCT02689284 · Gastric Cancer, Stomach Cancer Margetuximab 10 mg/kg, Margetuximab 15 mg | MGNX MacroGenics | Phase 1/2 | Completed | 95 | Jan 2021 | Registry ↗ |
| Mar 17, 2025 | Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastati… NCT02492711 · HER-2 Positive Breast Cancer, Metastatic Neoplasm Margetuximab, Trastuzumab | MGNX MacroGenics | Phase 3 | Completed | 624 | Aug 11, 2021 | Registry ↗ |
| Mar 13, 2025 | Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refract… NCT01828021 · Breast Cancer Margetuximab | MGNX MacroGenics | Phase 2 | Completed | 25 | Dec 7, 2016 | Registry ↗ |
| Mar 6, 2025 | MGD019 DART® Protein in Unresectable/Metastatic Cancer NCT03761017 · Squamous Cell Non Small Cell Lung Cancer, Prostate Cancer M… Lorigerlimab | MGNX MacroGenics | Phase 1 | Completed | 162 | Aug 29, 2024 | Registry ↗ |
| Feb 26, 2025 | Safety Study of MGAH22 in HER2-positive Carcinomas NCT01148849 · Breast Cancer, Gastric Cancer margetuximab | MGNX MacroGenics | Phase 1 | Completed | 66 | Jun 14, 2022 | Registry ↗ |
| Jan 30, 2024 | Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML) NCT02152956 · AML Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off, Flotetu… | MGNX MacroGenics | Phase 1/2 | Terminated | 244 | Jul 5, 2022 | Registry ↗ |
| Dec 21, 2023 | A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms NCT03219268 · Advanced Solid Tumors, Hematologic Neoplasms tebotelimab 1 mg, tebotelimab 3 mg | MGNX MacroGenics | Phase 1 | Completed | 277 | Feb 8, 2023 | Registry ↗ |
| Dec 20, 2023 | Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer NCT04634825 · Head and Neck Cancer, Head and Neck Neoplasms Enoblituzumab, Retifanlimab | MGNX MacroGenics | Phase 2 | Terminated | 62 | Jul 29, 2022 | Registry ↗ |
| Dec 20, 2023 | Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onse… NCT00920582 · Type 1 Diabetes Mellitus Teplizumab Herold Regimen, Placebo | MGNX MacroGenics | Phase 3 | Terminated | 254 | Apr 2012 | Registry ↗ |
| Dec 5, 2023 | The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabet… NCT00385697 · Type 1 Diabetes Mellitus Teplizumab, Placebo | MGNX MacroGenics | Phase 2/3 | Completed | 554 | Jun 2010 | Registry ↗ |
| Nov 3, 2023 | Monoclonal Antibody RAV12 and Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer NCT00625586 · Pancreatic Cancer RAV12, Gemcitabine | MGNX MacroGenics | Phase 2 | Terminated | 2 | Jan 21, 2009 | Registry ↗ |
| Aug 9, 2023 | Protege Extension Trial - Long Term Follow Up Trial for Subjects Who Completed the Protege Study (C… NCT00870818 · Type 1 Diabetes Mellitus Blood samples for safety, Patient reported outcome question… | MGNX MacroGenics | Not applicable | Terminated | 219 | Feb 2011 | Registry ↗ |
| Sep 2, 2022 | MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy NCT03570918 · HIV-1-infection MGD014 | MGNX MacroGenics | Phase 1 | Completed | 21 | Sep 28, 2021 | Registry ↗ |
| May 31, 2022 | Flotetuzumab Expanded Access Program NCT04678466 · Acute Myeloid Leukemia, AML flotetuzumab | MGNX MacroGenics | — | No longer available | — | — | Registry ↗ |
| May 19, 2022 | MGD009/MGA012 Combination in Relapsed/Refractory Cancer NCT03406949 · Advanced Solid Tumors obrindatamab, retifanlimab | MGNX MacroGenics | Phase 1 | Completed | 25 | Apr 27, 2022 | Registry ↗ |
| Feb 22, 2022 | Expanded Access to MGAWN1 in Subjects With Suspected West Nile Neuroinvasive Disease; Suspected Wes… NCT01206504 · West Nile Virus Infection MGAWN1 | MGNX MacroGenics | — | No longer available | — | — | Registry ↗ |
| Feb 22, 2022 | A Trial to Evaluate the Safety of a Single Intravenous Infusion of MGAWN1 in Healthy Adults NCT00515385 · West Nile Virus MGAWN1, MGAWN1 | MGNX MacroGenics | Phase 1 | Completed | 40 | Dec 2008 | Registry ↗ |
| Feb 22, 2022 | RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma NCT00101972 · Cancer monoclonal antibody RAV12 | MGNX MacroGenics | Phase 1 | Completed | 53 | May 2008 | Registry ↗ |
| Feb 10, 2022 | Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Sever… NCT00954915 · Psoriasis teplizumab | MGNX MacroGenics | Phase 1/2 | Terminated | 1 | Jul 2010 | Registry ↗ |
| Feb 10, 2022 | Treatment of West Nile Virus With MGAWN1 NCT00927953 · West Nile Neuroinvasive Disease, West Nile Virus Infection MGAWN1, Placebo - normal saline | MGNX MacroGenics | Phase 2 | Terminated | 13 | Feb 2011 | Registry ↗ |
| Feb 8, 2022 | Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck NCT04129320 · Head and Neck Cancer, Squamous Cell Carcinoma of Head and N… enoblituzumab, MGA012 | MGNX MacroGenics | Phase 2/3 | Withdrawn | 0 | Oct 2020 | Registry ↗ |
| Feb 8, 2022 | MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer NCT03531632 · Colorectal Cancer Metastatic MGD007 + MGA012 | MGNX MacroGenics | Phase 1/2 | Completed | 38 | Feb 8, 2020 | Registry ↗ |
| Feb 8, 2022 | Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors NCT02982941 · Neuroblastoma, Rhabdomyosarcoma Enoblituzumab | MGNX MacroGenics | Phase 1 | Completed | 25 | May 22, 2019 | Registry ↗ |
| Feb 8, 2022 | Safety Study of MGD009 in B7-H3-expressing Tumors NCT02628535 · Mesothelioma, Bladder Cancer MGD009 | MGNX MacroGenics | Phase 1 | Terminated | 67 | Nov 25, 2019 | Registry ↗ |
| Feb 8, 2022 | Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer NCT02381314 · Melanoma, Non Small Cell Lung Cancer enoblituzumab plus ipilimumab | MGNX MacroGenics | Phase 1 | Completed | 24 | Nov 9, 2017 | Registry ↗ |
| Feb 8, 2022 | Phase 1 Study of MGD010 in Healthy Subjects NCT02376036 · Healthy Subjects MGD010, Placebo | MGNX MacroGenics | Phase 1 | Completed | 73 | Feb 2017 | Registry ↗ |
| Feb 8, 2022 | Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma NCT02248805 · Colorectal Carcinoma MGD007 | MGNX MacroGenics | Phase 1 | Completed | 95 | Jul 2, 2018 | Registry ↗ |
| Feb 8, 2022 | Tissue Procurement Substudy for Participants in Study CP-MGA271-01 NCT01918930 · Melanoma MGA271 | MGNX MacroGenics | Phase 1 | Terminated | 6 | Oct 2016 | Registry ↗ |
| Feb 8, 2022 | Safety Study of MGA271 in Refractory Cancer NCT01391143 · Prostate Cancer, Melanoma MGA271 | MGNX MacroGenics | Phase 1 | Completed | 179 | Apr 18, 2019 | Registry ↗ |
| Feb 8, 2022 | Subcutaneous Administration of Teplizumab in Adults With Type 1 Diabetes NCT01189422 · Type 1 Diabetes Mellitus teplizumab or placebo | MGNX MacroGenics | Phase 1 | Terminated | 1 | Feb 2011 | Registry ↗ |
42 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 10:02 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances